Searchable abstracts of presentations at key conferences in endocrinology

ea0032p518 | Endocrine tumours and neoplasia | ECE2013

Neuroendocrine tumours (NETs) of lung: new data on atypical carcinoid and large cell neuroendocrine carcinoma from a French-Italian multicentric study

Marciello Francesca , Mercier Olaf , Ferolla Piero , David Planchard , Filosso Pier Luigi , Chapelier Alain , Grimaldi Franco , de Latour Bertrand Richard , Blanco Giusy , Guigay Joel , Monaco Guglielmo , Dartevelle Philippe , Papotti Mauro , Scoazec Jean-Yves , Colao Annamaria , Baudin Eric , Faggiano Antongiulio

Introduction: Natural history of lung neuroendocrine tumours (NETs) and in particular of two histological subtypes, atypical carcinoid (AC) and large cell neuroendocrine carcinoma (LCNEC), is poorly known.Aim of the study was to determine disease-free survival (DFS) and overall survival (OS) of sporadic, resectable, non-metastatic lung AC and LNEC.Patients and methods: This retrospective study involved 116 consecutive patients surg...

ea0032s31.2 | Clinical impact of rare mutations in endocrinology | ECE2013

Old and new MEN1 mutations

Calender Pr Alain

Multiple endocrine neoplasia type 1 (MEN1 – OMIM 131100) is considered as the major hereditary syndrome predisposing to multifocal endocrine tumors and a broad spectrum of non-endocrine lesions. Since the cloning of the MEN1 gene in 1997, a large number of studies have shown the large diversity of germline mutations found in patients with a poor genotype – phenotype correlation. Menin, the protein encoded by the MEN1 gene interacts with more than 30 nuclear/cellular ...

ea0022s13.3 | The TSH reference range | ECE2010

A critical synopsis of meta-analysis in the field of subclinical thyroid disease

Velkeniers Brigitte , Van Meerhaeghe Alain , Unuane David , Haentjens Patrick

Background: Currently, physicians remain uncertain whether to screen and/or treat subclinical thyroid disease. Many observational studies, including cross-sectional, case–control, and prospective cohort studies, have reported on the association between subclinical thyroid disease and an ‘outcome of interest’. All cause mortality, coronary heart disease, fracture risk, and pregnancy outcome may drive the decision to screen or treat subclinical thyroid disease.</p...

ea0021p323 | Reproduction | SFEBES2009

Kiss1 mRNA and kisspeptin immunoreactivity are differentially regulated in hypothalamus and visceral fat in a rat model of polycystic ovary syndrome (PCOS)

Brown Russell , Wilkinson Diane , Imran Syed , Caraty Alain , Wilkinson Michael

Introduction: The hypothalamic kiss1/kisspeptin system is pivotal in controlling fertility. However, kiss1 transcripts were also quantified in rat fat, where expression was regulated by oestradiol (Brown et al. 2008) and by dihydrotestosterone (DHT; Brown et al. 2009). In human fat, microarray analysis revealed abnormal, multiple gene expression in obese PCOS patients (Corton et al. 2007). In the present experiments we used a rat model (Manne...

ea0020s8.4 | Pituitary cell biology | ECE2009

Dual function of dopamine/somatostatin hybrid agonists

Saveanu Alexandru , Brue Thierry , Enjalber Alain , Jaquet Philippe , Barlier Anne

Somatostatin acts as an inhibitor of hormonal secretion and cell proliferation by acting through 5 somatostatin receptors subtypes (sst1–5). Coupling with Gi/o proteins is associated with effects on various transduction pathways, as adenylate cyclase inhibition or phosphatases activation. Dopamine receptor subtype 2 (D2DR) acts through coupling with similar G-proteins and transduction pathways. Sst, mostly sst2 and sst5, are coexpressed with D2DR in many neuroendocrine no...

ea0020p678 | Signal Transduction | ECE2009

The MAPKinases ERK1/2 take centre stage in somatotroph physiopathology

Pertuit Morgane , Romano David , Barlier Anne , Enjalbert Alain , Gerard Corinne

Somatotroph pituitary adenomas are characterized by unrestrained hormone secretion and cell proliferation alterations. In those tumors, the only mutation so far unequivocally identified is the gsp oncogene (Gsα protein gain of function mutation). Nethertheless, there is no clear difference in the clinical phenotypes of patients bearing tumor with the gsp oncogene (gsp+) or not (gsp−). In addition, an overexpression of the wild-type Gsα protein has been o...

ea0014s19.3 | Pituitary cell biology | ECE2007

Oncogene gsp and Gsα overexpression in pituitary cell biology

Barlier Anne , Gérard Corinne , Alain Enjalbert

Somatic mutations of the αs subunit of G proteins were initially reported by Landis and collaborators in 1989 in somatotroph tumors characterized by markedly high cAMP levels. These mutations are localized at two critical sites concerning the intrinsic guanosine triphosphatase activity of the protein leading to a constitutive activation of the adenylyl cyclase. The mutated protein has been named the gsp oncogene. On the other hand, Gsα mRNA level varied among ...

ea0049gp189 | Pituitary &amp; endocrine Tumours | ECE2017

Evaluation of pituitary toxicity after radiotherapy for cerebral chondrosarcomas in adult patients

Laroche Suzanne , Feuvret Loic , Beauchet Alain , Dendale Remi , Chanson Philippe , Bruckert Eric , Jublanc Christel

Pituitary dysfunction can be a consequence of cranial radiotherapy. It usually occurs years after the treatment. However little is known on risk factors for pituitary dysfunction. The object of this study was to evaluate radiation induced pituitary toxicity of proton beam therapy in a cohort of adult chondrosarcoma patients.The files of 113 patients were reviewed. Mean age at the beginning of radiotherapy was 43 years old (18–76). Mean dose delivere...

ea0044p57 | Bone and Calcium | SFEBES2016

Initial experience of a newly established intra-operative PTH service

Lekkakou Leoni , Kandaswamy Leelavathy , Rolli Alain , Ford Claire , Garnham Andrew , Spinou Catherine , Liew Lenny , Buch Harit

Background: A minimally invasive approach to primary hyperparathyroidism (PHPT) is equivalent to bilateral exploration when intraoperative parathyroid hormone (iPTH) monitoring is used. We have recently established an iPTH service jointly with Surgical and Clinical Chemistry teams and the aim of the study was to evaluate our initial results with its use.Patients and methods: We collected data from 18 operations for PHPT from October 2015, including one r...

ea0032p334 | Developmental Endocrinology | ECE2013

Somatostatin receptor sst2 transfer in somatolactotroph cell line. Constitutive activity and drug sensitivity

Roche Catherine , Graillon Thomas , Rasolonjanahary Ramahefarizo , Thirion Sylvie , Enjalbert Alain , Gerard Corinne , Barlier Anne

Somatostatin is a ubiquitous neuropeptidic inhibitor of various cellular functions including endocrine and exocrine secretion. Moreover, this peptide may control cell proliferation in normal and tumoral tissues. Somatostatin biological effects are mediated by five subtype of G protein-coupled receptor, sst1 through sst5. The somatostatin analogs have high affinity for sst2 receptor and the success of in vivo peptide therapy is correlated with high levels of sst2 in th...